(Alliance News) - Clinigen Group PLC on Thursday said it has signed an exclusive deal to distribute in the UK drugs developed by Paion AG.
Aachen, Germany-based Paion develops drugs used for hospital-based sedation, anesthesia and critical care. Clinigen is based in Burton-upon-Trent and signs partnerships with drug developers to help launch and distribute their products.
Paion's Byfavo drug, a sedative given to patients undergoing invasive medical procedures, was approved in the UK this year. It has two more products recently launched outside the UK - Giapreza, an injection to increase blood pressure, and Xerava, for treating complicated intra-abdominal infections.
Under the terms of the deal, Clinigen will supply and distribute Paion's licensed products in the UK.
"We are pleased to be partnering with Paion for their first commercial launch in the UK and to be able to offer Byfavo to healthcare providers across the UK through our lifecycle platform," Clinigen Chief Operating Officer Sam Herbert said.
Shares in Clinigen were up 0.4% to 617.50 pence in London. Paion was up 1.2% to EUR1.88 in Frankfurt.
By Ivan Edwards; ivanedwards@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
